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Thrombin is a serine protease playing an essential role in the blood coagulation cascade.
Recentwork, however, has identiﬁed a novel role for thrombin-mediated signaling pathways
in the central nervous system. Binding of thrombin to protease-activated receptors (PARs)
in the brain appears to have multiple actions affecting both health and disease. Speciﬁcally,
thrombin has been shown to lead to the onset of seizures via PAR-1 activation. In this
perspective article, we review the putativemechanisms bywhich thrombin causes seizures
and epilepsy.Wepropose a potential role of PAR-1 antagonists and novel thrombin inhibitors
as new, possible antiepileptic drugs.
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THROMBIN SIGNALING IN THE BRAIN
Thrombin is a serine protease, which plays an essential role in
the blood coagulation cascade (Siller-Matula et al., 2011). Upon
its formation following the enzymatic cleavage of prothrombin
by activated Factor X, thrombin regulates a cascade of proteolytic
events ultimately leading to the formation of blood clots (Lippi
et al., 2012). Lately, however, novel signaling cascades mediated by
thrombin have been discovered (Siller-Matula et al., 2011). Specif-
ically, through the activation of the protease-activated receptors
(PARs), thrombin seems to directly affect the activity of mul-
tiple cell types and regulate a variety of biological functions,
such as inﬂammation, leukocyte migration, cellular proliferation,
vascular permeability and tone, edema formation, and other pro-
cesses related to tissue repair (Coughlin, 2000, 2001; Sambrano
et al., 2001; Chen and Dorling, 2009; Schuepbach et al., 2009;
Spiel et al., 2011).
Protease-activated receptors belong to a unique family of G
protein-coupled receptors (Luo et al., 2007). Their activation is
initiated by an irreversible site-speciﬁc proteolytic cleavage in
the N-terminal extracellular region. The uncovered N-terminal
region then acts as a tethered ligand which activates the receptor
(Gingrich and Traynelis, 2000). PARs are expressed in the brain
and while PAR-2 represents a class of trypsin/tryptase-activated
receptors, PAR-1, PAR-3, and PAR-4 are most effectively activated
by thrombin (Gingrich and Traynelis, 2000). In the brain, PAR-1
has been detected in both neurons and astrocytes, with the latter
demonstrating stronger immunoreactivity in human brain tissue
(Junge et al., 2004). High levels of PAR-1 are detected in the hip-
pocampus, cortex, and striatum of humans (Junge et al., 2004).
While the molecular pathways activated by PAR-1 in neurons are
yet under investigation, in the brain PAR-1 activation has been
shown to modulate synaptic transmission and plasticity through
the enhancement of N-methyl-D-aspartate (NMDA) receptor
(NMDAR) currents (Gingrich et al., 2000; Lee et al., 2007; Maggio
et al., 2008). In addition, PAR-1 knockout animals present pro-
found deﬁcits in hippocampus-dependent learning and memory
processes (Almonte et al., 2007, 2013). Altogether, it seems that
PAR-1 plays a critical role in memory formation and synaptic
plasticity.
Interestingly, a variety of pathological conditions have been
associated with changes in the expression of PAR-1 in the brain. In
Parkinson’s disease, a signiﬁcant increase in the number of astro-
cytes expressing PAR-1 has been reported in the substantia nigra
pars compacta (Ishida et al., 2006). In addition, upregulation of
PAR-1 in astrocytes has been observed inHIV encephalitis, (Boven
et al., 2003) indicating that this receptormight be implicated in the
pathogenesis of neuroinﬂammation. This idea is supported by the
evidence of elevated levels of thrombin in an experimental model
of multiple sclerosis (Beilin et al., 2005) as well as in other inﬂam-
matory brain diseases (Chapman, 2006). Stimulation of PAR-1
by thrombin causes proliferation of glia and potentially produces
reactive gliosis, inﬁltrationof inﬂammatory cells, and angiogenesis
(Striggow et al., 2001). Finally, expression of PAR-1 is increased in
experimental models of Alzheimer’s disease (Pompili et al., 2004)
and brain ischemia (Striggow et al., 2001).
THROMBIN CAUSES SEIZURES AND EPILEPSY THROUGH
PAR-1 ACTIVATION
Serine proteases are normally expressed in the brain at very
low level (Luo et al., 2007). Nevertheless, their concentration
can increase abnormally following the breakdown of the blood–
brain barrier (BBB). Under this scenario, a large, non-selective
increase in the permeability of brain capillaries and tight junc-
tions takes place, allowing the entry of high molecular weight
proteins (Ballabh et al., 2004) and blood components into the
cerebral tissue. This event can occur under several neurological
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conditions (Ballabh et al., 2004; Tomkins et al., 2007), particu-
larly after hemorrhagic/ischemic stroke (Hjort et al., 2008; Bang
et al., 2009) or traumatic brain injury (TBI; Barzo et al., 1997;
Tomkins et al., 2008). Although there is a paucity of informa-
tion concerning the amount of thrombin crossing the BBB, it
has been demonstrated that thrombin levels increase more than
200-fold (from 100 pM to 25 nM) in the cerebrospinal ﬂuid of
patients with subarachnoid cerebral hemorrhage (Suzuki et al.,
1992). In addition, when the bleeding occurs directly within the
brain tissue, active thrombin and other proteases can freely dif-
fuse into the brain parenchyma until clotting closes off the injured
vessels. In this respect, our preliminary data suggest that under
experimental conditions, depletion of thrombin from the clot
appears to be continuous, with the concentration of thrombin
in cerebrospinal ﬂuid increasing several-folds over a 24-h time
window.
A direct consequence of the contact of thrombin with the brain
tissue is the onset of seizures. Lee et al. (1997) reported that intrac-
erebral injections of thrombin resulted in focal motor seizures.
Interestingly, thrombin injected together with its inhibitor alpha-
(2-naphthylsulfonyl-glycyl)-4-amidinophenylalanine piperidide
(alpha-NAPAP) did not cause any sign of either clinical or elec-
trographic seizures (Lee et al., 1997). Similarly, mice engineered
to lack protein Nexin-1, an endogenous thrombin inhibitor, have
an increased susceptibility to kainic acid-induced seizures (Luthi
et al., 1997). Our own work has demonstrated that thrombin-
induced seizures are mediated by activation of PAR-1 (Maggio
et al., 2008). In hippocampal slices, thrombin at a concentration
of 5 nM (1 U/ml) increases spontaneous ﬁring of CA3 pyramidal
cells (Maggio et al., 2008). In order to examine whether thrombin
facilitates the onset of epileptic discharges in conditions mimick-
ing a BBB breakdown in the slice (Chen and Swanson, 2003; Beart
and O’Shea, 2007), we exposed neurons to thrombin in presence
of elevated [K+]o or low levels of glutamate. In normal slices,
addition of 4 mM K+ did not produce any noticeable sponta-
neous seizures, which were clearly seen when [K+] were raised by
15 mM. Similarly, 500 μM but not 100 μM glutamate produced
spontaneous seizure-like activity in the slice. Strikingly, thrombin
facilitated the response to the lower concentration of K+ (4 mM)
and glutamate (100 μM) to produce seizure-like activity. This
activity was mediated by PAR-1 activation, since it was mimicked
by a peptide agonist of the receptor and blocked by its antagonist
SCH79797. Interestingly, the facilitatory actionof thrombinon the
production of seizure-like activity did not depend on NMDARs
as it was not affected by the selective NMDAR-inhibitors ifen-
prodil or by 2R-amino-5-phosphonovaleric acid (APV). Recently,
Isaeva et al. (2012) exposed hippocampal slices from immature
rats (P6 to P15) to large concentrations of thrombin (10 U/ml) to
ﬁnd that thrombin depolarized membrane potential of neurons
and produced a hyperpolarizing shift of tetrodotoxin-sensitive
INap through a PAR-1-mediated mechanism (Isaeva et al., 2012).
In addition, we have reported that thrombin affects synaptic
transmission in hippocampal CA3 neurons by enhancing both fre-
quency and amplitude of mEPSCs while reducing frequency and
amplitude of mIPSCs (Maggio et al., 2012). Taken together, these
studies clearly indicate a proepileptic effect of thrombin which
upon PAR-1 activation induces membrane and synaptic changes
FIGURE 1 |Thrombin leads to seizures through PAR-1 activation.
Increased levels of thrombin in the brain lead to PAR-1 activation. PAR-1
promotes membrane depolarization due to activation of INap and altered
balance of excitatory/inhibitory synapses leading to seizures.
leading to seizures (Figure 1). Less clear, however, is whether
the thrombin-induced increase in neuronal activity could lead
to epilepsy later on. Indeed, it has been demonstrated that high
concentrations of thrombin, usually reached in pathological set-
tings following thrombin extravasation into the brain,may induce
apoptosis (Lee da et al., 2006; Wang et al., 2006; Xi et al., 2006;
Luo et al., 2007). Accordingly, thrombin-inducedneuronal cell loss
could lead to circuit reorganization and onset of epilepsy. While
circuit reorganization following injury is a well known cause of
hyper excitability (Heinemann et al., 2002; Heinemann, 2004), no
information is currently available on the possible role of thrombin
and PAR-1 activation in this situation.
PAR-1 ANTAGONISTS AND THROMBIN INHIBITORS AS NEW
ANTIEPILEPTIC DRUGS?
Seizures and epilepsy are commonly observed in conjunction with
stroke, TBI, and central nervous system infections, all conditions
known to result in compromised BBB function (Tomkins et al.,
2001; Ballabh et al., 2004). Regional patterns of BBB breakdown
have been described during epileptiform seizures induced in ani-
malmodels by various convulsive agents (Nitsch andKlatzo,1983).
FollowingBBBbreakdown, seizures result from the exposure of the
brain to serum components such as thrombin due to the increased
permeability of the BBB (Kelly, 2008). In fact, even in the absence
of hemorrhage, BBB breakdownmay activate the coagulation cas-
cade leading to intracerebral generation of thrombin (Stein et al.,
2002; Chodobski et al., 2011; Pisapia et al., 2012). In this setting an
enduring BBB breakdown due to uncontrolled seizures may lead
to a continuous leak of thrombin into the brain, which in turn
sustains the epileptic process (Figure 2).
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FIGURE 2 | In chronic epilepsy, thrombin constantly sustains the
epileptic process. In chronic epilepsy, recurrent seizures lead to the
breakdown of BBB. Extravasation of thrombin from the blood into the brain
tissue activates PAR-1 in the brain. PAR-1 activation sustains or even
enhances the epileptogenic processes responsible for the refractoriness of
such syndrome. The use of either PAR-1 antagonists and/or serine
proteases inhibitors could break this vicious cycle and prevent the
occurrence of refractoriness.
If thrombin indeed is the major reason for seizures in this con-
dition, it is tempting to speculate that PAR-1 antagonists and/or
thrombin inhibitors could act as potential antiepileptic drugs.
PAR-1 antagonists are a class of drugs currently tested in the
context of cardiovascular diseases (Ahn et al., 2003; Landis, 2007;
Lee and Hamilton, 2012). They are non-peptide small molecular
compounds which differ in their effectiveness to inhibit PAR-1
(Ahn et al., 2003). They have both anticoagulant (Wielders et al.,
2007) and antiaggregant (Lee and Hamilton, 2012) properties.
However, unlike a direct thrombin inhibitor, they are thought to
have minimal bleeding side-effects due to the inability of blocking
the enzymatic action of thrombin in the coagulation cascade. We
(Maggio et al., 2008, 2012) and others (Isaeva et al., 2012) have
indeed shown that PAR-1 antagonists block the proepileptogenic
effects of thrombin in vitro, however, no data currently exist on the
role of PAR-1 antagonists as antiepileptic drugs in animal mod-
els of epilepsy following BBB breakdown. Furthermore, it is not
known whether thrombin and PAR-1 levels are increased in the
brains of experimental animals undergoing chronic epilepsy. In
this context, our preliminary data based on Li2+- pilocarpine
treated animals do show that this might indeed be the case.
Interpretation of clinical data might provide important insights
as well. Cardiac surgery has been associated with a high rate of
seizures in the post-operative settings (Goldstone et al., 2011a,b;
Hervey-Jumper et al., 2011). Thus, are patients treated with PAR-1
antagonists as prevention to reduce the prothrombotic risk occur-
ring in cardiothoracic surgery (Landis, 2007) going to show less
seizures in their post-operative outcomes?
Thrombin is the target of a newly developed class of antico-
agulants proposed as alternatives to vitamin K-dependent antico-
agulants for the prevention of stroke and systemic embolism in
patients with atrial ﬁbrillation (Zikria and Ansell, 2009; Dentali
et al., 2012; Haft, 2012). Do these molecules have an antiepileptic
activity as well? In this respect, the novel direct thrombin inhibitor,
dabigatran, which blocks the proteolytic activity of thrombin,
might mimic the antiepileptic effect of alpha-NAPAP by prevent-
ing the thrombin-dependent activation of PAR-1. A similar result,
using a different mechanism may be achieved by the novel direct
Factor X inhibitors, apixaban and rivaroxaban, which halt Fac-
tor X from converting prothrombin to thrombin. Currently, no
clinical and experimental data are available to analyze whether
these molecules might have a role in the prevention of seizures
and epilepsy upon brain exposure to high intracerebral concen-
trations of thrombin. Indeed, it might be interesting to evaluate
whether patients taking direct thrombin inhibitors for secondary
stroke prevention are less prone to the development of seizures, a
known complication of stroke. This being the case, our approach
justiﬁes the use of these drugs as more advantageous compared
to the old vitamin K-dependent anticoagulants. A possible disad-
vantage for the use of these drugs in epileptic patients might be
related to the increased risk of bleeding in people experiencing
recurrent falls due to seizures. This is certainly possible, however,
studies are needed to evaluate whether the dosage required for
full anticoagulation are similar to the ones needed to reach an
antiepileptic effect: thrombin concentrations are far higher in the
serum (Siller-Matula et al., 2011) than in the brain following BBB
breakdown (Striggow et al., 2000). The use of these drugs might
as well be proposed in patients which may develop epilepsy fol-
lowing brain hemorrhage. This should however be very carefully
considered by taking into account the type and modalities of the
bleeding as well as possible continuation of anticoagulation in a
population of patients at risk of recurrence.
In conclusions, work from recent years has disclosed a novel
and clinically highly relevant role for thrombin in the pathogene-
sis of hyperexcitability in neuronal networks and the development
of seizures and epilepsy. However, more data are needed to eval-
uate the precise role of thrombin in epilepsy. The identiﬁcation
of the thrombin-PAR-1 pathway playing a fundamental role in
the pathophysiology of epilepsy may lead to the development of
new therapeutic strategies and provide a rationale for testing PAR-
1 antagonists and/or thrombin inhibitors in animal models of
epilepsy.
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